Newsome SD, et al. A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis. Abstract 60. ECTRIMS 11-13 sept 2019, Stockholm, Zweden.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024